GLP-1 Dynamics Continue: Eli Lilly Significantly Raises Revenue Forecast After Strong Quarter
Reading Time: 2 minutes
Operational Record Numbers: In the third quarter, the company’s revenue rose to $24.4 billion, while earnings per share of $7.48 significantly exceeded the consensus estimate of $6.61. Success Factor Mounjaro: The blockbuster for the treatment of type-2 diabetes and obesity contributed $10.723 billion – an increase of 65 percent from the previous year. Shared Outlook: The annual revenue forecast for 2026 rises to up to $92 billion, while expenses for R&D acquisitions slightly dampen earnings per share. The US pharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
